Simple Blood Test Measures Repetitive DNA for Early Cancer Detection

Researchers at Johns Hopkins Medicine (Baltimore, MD, USA) leveraged this insight to improve a test designed for early cancer detection. They began their study with a sample size that was ten times larger than what is usually seen in such research. Alu elements are relatively small, each being about 300 base pairs in length within the vast 2 billion-step DNA ladder. Yet, changes in the proportion of Alu elements in blood plasma are consistent, irrespective of the cancer’s origin. The research team had previously developed a test for detecting aneuploidy, a condition involving chromosome copy number alterations common in cancers, using a liquid biopsy blood test. This test identifies fragments of cancer cell DNA circulating in the bloodstream. While conducting this research, they noticed an unusual signal that differentiated between cancer and non-cancer, which wasn’t attributed to changes in chromosome numbers. Consequently, they combined their original test, which analyzed 350,000 repetitive DNA locations, with an unbiased machine learning approach.

In their study, the team analyzed samples from 3,105 individuals with solid tumors and 2,073 without cancer, covering 11 types of cancer and evaluating 7,615 blood samples. The repetitive DNA sequences were examined repeatedly to assess the accuracy of the model. They achieved a specificity rate of 98.9%, crucial for minimizing false positives, especially when screening asymptomatic individuals to avoid erroneous cancer diagnoses. In an independent validation set, incorporating Alu elements into the machine learning model identified 41% of cancer cases that were missed by eight existing biomarkers and the team’s earlier test. The most significant contributor to cancer detection was identified as AluS, the largest subfamily of Alu elements. People with cancer were found to have lower levels of AluS in their blood plasma than typical. The researchers expect their Alu-based cancer detection method to complement the array of existing cancer diagnostic tools. Their next step involves identifying the most promising biomarkers and combining them for enhanced efficacy.

Related Links:
Johns Hopkins Medicine